BACKGROUND Pre-clinical data show that overlapping scaffold segments show delayed healing and strut coverage compared to nonoverlapping scaffold segments. Little is known whether this may have an impact on clinical outcome.
RESULTS
No differences in baseline patient and lesion characteristics between both patient groups were noted, apart from the significant longer lesion length in the overlapping scaffold group (16.7AE7.3 versus 11.6AE4.4 mm, [p<0.0001; 95% CI: 3.7-6.4]) and subsequently less lesion type B1 and more B2. Furthermore, more patients were treated for stable angina in the overlapping scaffold group (72% versus 54%, p¼0.0003). In the overlapping scaffold group 41/125 (33%) lesions were > 20 mm long, compared to 33/734 (5%) lesions in the nonoverlapping group, p<0.0001. The 1 year clinical outcome is summarized in the table below. Scaffold Thrombosis is reported according ARC and Myocardial Infarction according protocol definitions. properties. The drug dose is 5 mg per mm of scaffold length; the device is available in multiple diameters (2.5 -3.5 mm) and lengths (14, 18 and 28 mm). The DESolve Nx study is multi-center evaluation of the safety and efficacy of the DESolve NEBCSS in patients with single, de novo, native coronary artery lesions.
METHODS A total of 126 patients were enrolled in this prospective registry. Patients receiving the study device were analyzed for multiple clinical endpoints including: device and procedure success; Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, or clinically-indicated target lesion revascularization (CI-TLR); Target Vessel Revascularization, (CI-TVR) and stent thrombosis assessed at 1, 6 and annually to 5 years. All patients underwent angiographic assessment at 6 months and a subset of patients underwent IVUS and OCT assessment also at 6 months and imaging 12 months using multislice computed tomography (MSCT). Additionally, at single centers, multi-modality imaging was completed at 18 months and 3 years.
RESULTS Mean age at baseline was 62 years, 32% were females, and 21% diabetics. Lesion length was 11.2 mm, RVD was 3.06 mm, and 18.3% showed moderate-to-heavy calcification. Six-month QCA demonstrated low mean in-scaffold late lumen loss (0.20 mm), 18.3% DS and an MLD of 2.45 mm. Serial IVUS at baseline and 6 months demonstrated a significant increase in mean lumen (D 10.0%, p ¼ < 0.001) and scaffold areas (D 15.7%, p ¼ < 0.001) and low % volume obstruction ( RESULTS Among the 1851 patients, the mean SRI was 85.4% AE 23.4%, ranging from 4% to 100%. Complete revascularization (SRI¼100%) was achieved in 64.3% of patients, SRI¼ 50-99% in 472 patients (25.5%), and SRI <50% in 189 patients (10.2%). The 2-year rates of mortality (0.4%, 1.9%, and 2.7%, p¼0.001) and MACE (6.0%, 11.4%, and 10.1%, p<0.001) were higher in patients with lower SRI. By ROC analysis, an SRI cut-off of 85% showed the best prognostic accuracy for 2-year mortality. A SRI of !85% had similar low allcause death and cardiac death rates when compared to complete (SRI¼100%) revascularization (Figure) . By multivariable analysis, SRI was a strong predictor of 2-year mortality (HR: 4.20, 95% CI: 1.46-12.08, p¼0.008) and 2-year MACE (HR: 1.59, 95% CI: 1.14-2.23, p¼0.007).
CONCLUSIONS In patients with complex CAD undergoing EES-PCI, the SRI was identified as a strong predictor of 2-years mortality and MACE. Given its correlation with mortality, the SRI may be useful in assessing the degree of revascularization after PCI, with SRI !85% as a reasonable goal. CONCLUSIONS The rates of chest pain were low and similar in patients with bifurcated versus non-bifurcated target lesions, who showed favorable clinical outcomes at 1 and 2-year follow-up after treatment with contemporary flexible drug-eluting stents. 
